Table 1.
Demographic characteristics of subjects who participated in the phase 2 trial.
| Vaccine (n = 50)18–49 years2 Doses | Vaccine (n = 50)≥ 50 years2 Doses | Vaccine (n = 50)18–49 years1 Dose | Vaccine (n = 50)≥ 50 years1 Dose | |
|---|---|---|---|---|
| Sex | ||||
| Female | 30 (60·0%) | 31 (62·0%) | 28 (56·0%) | 34 (68·0%) |
| Male | 20 (40·0%) | 19 (38·0%) | 22 (44·0%) | 16 (32·0%) |
| Ethnicity | ||||
| Caucasian | 12 | 2 | 14 | 7 |
| Asian | 38 | 48 | 36 | 43 |
| Age, years | 35·0 (25·3, 41·8) | 55·0 (52·0, 61·0) | 32·0 (24·3, 41·0) | 54·5 (52·0, 57·3) |
| 20·0–49·0 | 50·0–66·0 | 19·0–49·0 | 51·0–70·0 | |
| Height, cm | 168·5 (165·0, 173·5) | 169·0 (164·3, 171·0) | 169·5 (165·5, 174·0) | 168·0 (164·0, 171·0) |
| 156·0–191·0 | 152·0–180·0 | 155·0–179·0 | 153·0–175·0 | |
| Body weight, kg | 71·0 (61·8, 75·8) | 83·0 (76·8, 87·0) | 71·5 (61·0, 82·8) | 79·0 (73·0, 85·0) |
| 51·0–95·0 | 58·0–97·0 | 53·0–110·0 | 53·0–95·0 |
Data are presented as Median (IQR) and min-max range.